Drug Trial Radar · NCT05076617
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
300
Planned (sponsor's estimate)
Start
Feb 3, 2022
Primary completion
Nov 30, 2028
Study completion Nov 30, 2028
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Oct 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the long-term safety and tolerability of Staccato alprazolam.
Conditions
- Stereotypical Prolonged Seizures
Interventions
Staccato alprazolamDrug
* Pharmaceutical form: Inhalation powder * Route of administration: Inhalation Participants will receive Staccato alprazolam during the Treatment Period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of treatment-emergent adverse events (TEAEs)Time frame: From Baseline up to the End of Study Visit (up to 78 months)
- Frequency of TEAEs leading to withdrawal from studyTime frame: From Baseline up to the End of Study Visit (up to 78 months)
- Frequency of serious TEAEsTime frame: From Baseline up to the End of Study Visit (up to 78 months)
Locations
133 sites in 12 countries. Site status is shown where the registry gives one.
Ep0165 50506
Phoenix, Arizona
Ep0165 50720
Scottsdale, Arizona
Ep0165 50118
Downey, California
Ep0165 50416
La Jolla, California
Ep0165 50702
Long Beach, California
Ep0165 50716
Sacramento, California
Ep0165 50088
Washington D.C., District of Columbia
Ep0165 50515
Gulf Breeze, Florida
Ep0165 50508
Jacksonville, Florida
Ep0165 50342
Jacksonville, Florida
Ep0165 50199
Miami, Florida
Ep0165 50676
Miami, Florida
Ep0165 50509
Orlando, Florida
Ep0165 50703
Rockledge, Florida
Ep0165 50308
Tampa, Florida
Ep0165 50323
Honolulu, Hawaii
Ep0165 50512
Boise, Idaho
Ep0165 50493
Chicago, Illinois
Ep0165 50504
Fort Wayne, Indiana
Ep0165 50517
New Orleans, Louisiana
Ep0165 50615
Boston, Massachusetts
Ep0165 50047
Boston, Massachusetts
Ep0165 50507
St Louis, Missouri
Ep0165 50299
New Brunswick, New Jersey
Ep0165 50497
Amherst, New York
Ep0165 50298
New York, New York
Ep0165 50490
New York, New York
Ep0165 50518
New York, New York
Ep0165 50034
Rochester, New York
Ep0165 50514
Charlotte, North Carolina
Ep0165 50715
Durham, North Carolina
Ep0165 50701
Portland, Oregon
Ep0165 50096
Philadelphia, Pennsylvania
Ep0165 50364
Philadelphia, Pennsylvania
Ep0165 50089
Philadelphia, Pennsylvania
Ep0165 50511
Pittsburgh, Pennsylvania
Ep0165 50491
Pittsburgh, Pennsylvania
Ep0165 50700
Chattanooga, Tennessee
Ep0165 50513
Memphis, Tennessee
Ep0165 50103
Nashville, Tennessee
Showing 40 of 133 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.